FDA Approved: AVAPRO — Supplemental Application (Sanofi-Aventis U.S. LLC)

View source ↗

Summary

The FDA approved a supplemental labeling change for AVAPRO (irbesartan) filed by Sanofi-Aventis U.S. LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Hypertension

Drugs mentioned

• AVAPRO (irbesartan)

Snippet

SUPPL AP for AVAPRO (IRBESARTAN)